UPCOMING SESSIONS in ET
Fri, Nov 20, 2026
6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness Hamide Eygoren Register
UPCOMING SESSIONS in ET
Fri, Nov 20, 2026 · 6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness
Hamide Eygoren
Register
View all sessions

ATTR-CM: A Care Partner’s Perspective

People living with ATTR-CM often rely on strong support systems. This video highlights caregivers, their essential role, and the meaningful impact they make every day.

What is Attruby?
 
Attruby is a prescription medicine used to treat adults with a disease that affects the heart muscle called cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), to reduce death and hospitalization related to heart problems. It is not known if Attruby is safe and effective in children.  

date of the ARTICLE publication
Jul 21, 2026

Living with Hope After an ATTR-Cardiac Amyloidosis (ATTR-CM) Diagnosis

Here, you’ll meet John, Gina, Ken & Mary, whose lives have all been affected by ATTR-cardiac amyloidosis (ATTR-CM). John and Ken share what signs and symptoms led to their diagnoses, along with their experiences finding treatment with Attruby. The two couples reflect on the treatment journey and how they find joy in everyday moments, big and small.  

What is Attruby? 

date of the ARTICLE publication
Jun 18, 2026

Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial

Key Points

Question  Is long-term treatment with acoramidis in transthyretin amyloid cardiomyopathy associated with sustained clinical benefit through 54 months in the open-label extension of ATTRibute-CM?

News Date

Prothena Announces Achievement of $50 Million Clinical Milestone in ATTR Amyloidosis with Cardiomyopathy

  • Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3
  • Prothena has now earned $150 million to date of the $1.2 billion total eligible milestone payments from Novo Nordisk

DUBLIN--(BUSINESS WIRE)--$PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company earned a $50 million milestone payment from Novo Nordisk related

News Date